Temozolomide and Oral VP-16

Titre officiel

A Phase I/II Trial of Temozolomide and Escalating Doses of Oral VP-16 for Children and Young Adults with Recurrent Brain Tumours

Sommaire:

Le pronostic des enfants atteints d’une affection maligne récidivante du système nerveux central, tels le médulloblastome, l’épendymome et le glioblastome multiforme, est sombre. Bien que la survie de ces enfants puisse être prolongée par des techniques novatrices, telles la chirurgie guidée par l’image, la radiochirurgie stéréotaxique et la chimiothérapie à forte dose combinée à une autogreffe de cellules souches de rattrapage, la plupart des enfants succombent tout de même à la maladie récidivante. Les efforts faits pour traiter la récidive tumorale chez ces enfants ont été entravés par la résistance de la tumeur à la radiothérapie, la dissémination locale de la tumeur à l’extérieur des champs irradiés, la résistance à la chimiothérapie et l’incapacité des agents chimiothérapeutiques à traverser la barrière hémato-encéphalique.

Bien que les cliniciens aient étudié de nombreux agents chimiothérapeutiques pour traiter les tumeurs cérébrales récidivantes chez les enfants, les résultats pour ces enfants demeurent insatisfaisants. On doit mettre au point de nouveaux agents et étudier la possibilité d’utiliser des traitements combinant des agents anciens et de nouveaux agents.

Description de l'essai

Temozolomide is a recently-developed cytotoxic agent that is currently being tested against a broad spectrum of malignancies. In animal models Temozolomide has been shown to penetrate into the central nervous system (CNS).  This appears to be the case in humans as well. Many patients with newly diagnosed or recurrent malignant gliomas have responded to the drug.

There are few studies of temozolomide in children. Although there were few responses in children with high-grade or low-grade glioma, a number of patients had prolonged stable disease. Because overall responses to temozolomide have been modest and short-lived, temozolomide may prove to be more effective in combination with other agents.

Etoposide (VP-16) is a type II topoisomerase inhibitor which, like temozolomide, penetrates the central nervous system and has activity against brain tumours.  While VP-16 has proven effective when administered intravenously, it has been shown in several studies that its efficacy is schedule-dependent and that it may be more effective when given as several small doses rather than as a single larger one. 

Orally-administered VP-16 has been remarkably effective against a broad spectrum of pediatric brain tumours when administered as a 3 week course at a dose of 50 mg/m2/day. VP-16, like Temodar, may be more effective when used in combination with other agents.  There may be a synergistic effect when temozolomide and VP-16 are used in combination.

This clinical trial proposes a combination therapy with temozolomide and oral VP-16 for children with recurrent or progressive brain tumours.  This combination holds great appeal because:

  • Both agents have established efficacy against a broad spectrum of brain tumors; 
  • There may be synergy when the 2 are used together;
  • Their mechanisms of cytotoxicity are completely different;
  • There is only mild toxicity when each is used alone;
  • Both agents can be administered orally, thus increasing their appeal to patients and treating physicians. 

Because the 2 agents have not been given together in children, the trial will be conducted as a phase I study with a fixed dose of temozolomide (180 mg/m2/day for 5 days) and a dose escalation of oral VP-16 (from 50 mg/m2/day for 8 days to 50 mg/m2/day for 20 days).  Toxicity may be more pronounced in children who received craniospinal irradiation; thus children in this study will be stratified into two groups – those who received CSI and those who did not.  Once the maximum tolerated dose of oral VP-16 is established in each of these groups, subsequently enrolled patients will be treated at that dose.

Outcomes:

  • To determine whether the investigational drug temozolomide can be given safely in combination with a standard drug VP-16. (to determine the maximum tolerated dose and dose limiting toxicity of oral VP-16 in combination with a fixed dose of temozolomide in children and young adults with recurrent brain tumours)
  • To determine whether these two drugs in combination will be of benefit in controlling the growth of brain tumors. (to determine the response of children and young adults with recurrent brain tumors to temozolomide and oral VP-16)
  • To evaluate the good and bad effects of different doses of VP-16.

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer